Weak response forces ICICI Sec to cut IPO size

FPJ BureauUpdated: Wednesday, May 29, 2019, 11:15 PM IST
article-image

New Delhi : ICICI Securities on Monday reduced the size of its initial public offer to little over Rs 3,500 crore after the sale elicited a sluggish response, especially from high net worth individuals.

The share sale of the leading brokerage firm — which was to raise up to Rs 4,016 crore — received around 88 per cent subscription, including the anchor portion, on the last day on Monday.

In a statement, ICICI Securities said it has “successfully closed its proposed Offer for Sale (OFS) and raised around Rs 3,500 crore”.

This indicates that the size of the IPO has been reduced in the wake of sluggish response. Data available with the exchanges till 1945 hours showed that the offer was subscribed 78 per cent, excluding the anchor portion. It received bids for 3,46,75,396 shares against the total issue size of 4,42,25,343 shares (without anchor portion), according to the NSE data.

(If you have a story in and around Mumbai, you have our ears, be a citizen journalist and send us your story here. )

(To receive our E-paper on WhatsApp daily, please click here.  To receive it on Telegram, please click here. We permit sharing of the paper's PDF on WhatsApp and other social media platforms.)

RECENT STORIES

Earnings 2023 LIVE: Indigo net profit jumps to Rs 1,422.61 cr; Paytm's losses narrow down to Rs...

Earnings 2023 LIVE: Indigo net profit jumps to Rs 1,422.61 cr; Paytm's losses narrow down to Rs...

Tech layoffs: Apple CEO Tim Cook says job cuts will be last resort

Tech layoffs: Apple CEO Tim Cook says job cuts will be last resort

Vodafone-Idea AGR saga: A breakdown of dues and a complete timeline of the case

Vodafone-Idea AGR saga: A breakdown of dues and a complete timeline of the case

Government rescues Vodafone Idea, converts dues into 35% stake

Government rescues Vodafone Idea, converts dues into 35% stake

Another blow for Indian pharma, drug linked to vision loss in US recalled

Another blow for Indian pharma, drug linked to vision loss in US recalled